A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
Nature Medicine2012Vol. 18(4), pp. 521–528
Citations Over TimeTop 1% of 2012 papers
King Pan Ng, Axel M. Hillmer, Charles Chuah, Wen Chun Juan, Tun Kiat Ko, Audrey S.M. Teo, Pramila Ariyaratne, Naoto Takahashi, Kenichi Sawada, Fei Yao, Sheila Soh, Wah Heng Lee, David C.S. Huang, John Carson Allen, Xing Yi Woo, Niranjan Nagarajan, Vikrant Kumar, Anbupalam Thalamuthu, Wan Ting Poh, Ai Leen Ang, Hae Tha Mya, Gee Fung How, Li Yi Yang, Liang Piu Koh, Balram Chowbay, Chia-Tien Chang, Veera Sekaran Nadarajan, Wee Joo Chng, Hein Than, Lay Cheng Lim, Yeow Tee Goh, Shenli Zhang, Dianne Poh, Patrick Tan, Ju‐Ee Seet, Mei‐Kim Ang, Noan‐Minh Chau, Quan‐Sing Ng, Daniel S.W. Tan, Manabu Soda, Kazutoshi Isobe, Markus M. Nöthen, Tien Yin Wong, Atif Shahab, Xiaoan Ruan, Valère Cacheux-Rataboul, Wing‐Kin Sung, Eng Huat Tan, Yasushi Yatabe, Hiroyuki Mano, Ross A. Soo, Tan Min Chin, Wan‐Teck Lim, Yijun Ruan, S. Tiong Ong
Related Papers
- → Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling(2016)38 cited
- → Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines(2000)70 cited
- → Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia(2015)
- Studies on Src tyrosine kinase in tumorigenic cell growth and invasion(2008)
- → Assessment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors(2017)